[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Ratnagiri R, Singh SS, Majhi U, Kathiresan, Sateeshan: Large-cell neuroendocrine carcinoma of the kidney: Clinicopathologic features. Indian J Urol; 2009 Apr;25(2):274-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell neuroendocrine carcinoma of the kidney: Clinicopathologic features.
  • Carcinoid tumors are the most common entities reported in the kidney.
  • There have been only a couple of case series of non-carcinoid neuroendocrine tumors of the kidney reported in literature.
  • Surgical resection appears to be the best available treatment modality.
  • Chemotherapy has been attempted with dismal results.
  • We report a patient with a large cell neuroendocrine carcinoma of the kidney, who underwent radical resection and is doing well on follow-up.
  • The diagnosis was confirmed by immune-histochemistry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2007 Nov;100(5):1030-5 [17784891.001]
  • [Cites] Ann Pathol. 2000 Sep;20(4):357-60 [11015655.001]
  • [Cites] Scand J Urol Nephrol. 1996 Aug;30(4):325-7 [8908658.001]
  • [Cites] Curr Opin Oncol. 2005 Jul;17(4):386-91 [15933475.001]
  • (PMID = 19672368.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2710086
  • [Keywords] NOTNLM ; Immuno histochemistry / kidney / neuroendocrine tumors
  •  go-up   go-down


2. Chung CH, Park CY: Small cell carcinoma of the kidney. Korean J Intern Med; 2006 Sep;21(3):191-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the kidney.
  • Up to 5% of all small cell carcinomas develop at extrapulmonary sites.
  • Primary small cell carcinomas originating in the kidney are extremely rare neoplasms.
  • Here we report a case of primary small cell carcinoma of the kidney.
  • A nephrectomy was performed on a 52-year-old female patient to remove a large tumor located in the right kidney.
  • The histology and immunohistochemistry of the resected tumor revealed a pure small cell carcinoma with invasion into the renal capsule.
  • The patient received postoperative adjuvant chemotherapy with etoposide and cisplatin.
  • The patient has been monitored with regular check ups and remains stable with no recurrence at 28 months after the initial diagnosis.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Kidney Neoplasms / diagnosis. Nephrectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 May 1;79(9):1729-36 [9128989.001]
  • [Cites] Pathol Int. 1998 May;48(5):412-5 [9704349.001]
  • [Cites] Semin Oncol. 1982 Dec;9(4):484-96 [6302908.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):274-7 [12908782.001]
  • [Cites] Jpn J Clin Oncol. 2004 May;34(5):250-4 [15231859.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1436-41 [12627507.001]
  • (PMID = 17017670.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3890724
  •  go-up   go-down


3. Miyagi T, Fuse H, Takashima M, Yotsuyanagi S, Imao T, Uchibayashi T, Namiki M, Kasahara T, Kasajima S, Nonomura A: [Primary small cell carcinoma of the kidney: a case report]. Hinyokika Kiyo; 2001 Jun;47(6):411-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary small cell carcinoma of the kidney: a case report].
  • Computed tomographic (CT)-scan and angiography showed large renal tumor with liver invasion and tumor thrombosis in the vena cava.
  • Percutaneous biopsy of the renal tumor revealed small cell carcinoma.
  • Chemotherapy including cisplatinum and etoposide was performed without success.
  • He died 6 months after the diagnosis.
  • Autopsy specimen revealed primary small cell carcinoma of the right kidney.
  • To our knowledge, this is the seventh case as primary renal small cell carcinoma in the world literature.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Kidney Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11496397.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


Advertisement
4. Kinoshita T, Inoue H, Kinouchi T, Kobayashi M, Takada T, Hara T, Hatano K, Nonomura N: Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report. Int J Urol; 2010 Mar;17(3):286-8
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report.
  • We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib.
  • Complete resection of the left renal mass measuring 7.2 x 6.6 cm seemed to be difficult at diagnosis because of large renal hilar lymph nodes.
  • Two-dimensional computed tomography revealed 60%, 78% and 84% reduction in the primary renal tumor, lung metastatic nodules and lymph nodes, respectively.
  • Tumor shrinkage allowed for complete resection of the left kidney and the lymphadenopathy.
  • Pathological findings revealed that over 90% of the renal tumor was substituted by necrotic fibrotic tissue and that the residual neoplastic component was diagnosed as clear cell carcinoma.
  • At 6 months after radical nephrectomy, a new computed tomography scan revealed no evidence of disease with the disappearance of lung nodules.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Benzenesulfonates / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Pyridines / administration & dosage
  • [MeSH-minor] Aged, 80 and over. Combined Modality Therapy. Female. Humans. Nephrectomy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Preoperative Care. Severity of Illness Index. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20409221.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


5. Horiguchi A, Uchida A: [Advanced renal cell carcinoma showing a different response to two types of interferon-alpha]. Nihon Hinyokika Gakkai Zasshi; 2004 Jan;95(1):50-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced renal cell carcinoma showing a different response to two types of interferon-alpha].
  • Interferon (IFN)-alpha has been widely used in systemic therapy for advanced renal cell carcinoma (RCC).
  • IFN-alpha is represented by a large family of structurally related genes expressing at least 14 subtypes, each of which shows quantitatively distinct patterns of biological activities.
  • Although those distinct patterns of biological activities of IFN-alpha subtypes against renal cancer cell lines have been demonstrated, there is no report that demonstrates the difference in each subtype-induced antitumor activity in patients with RCC.
  • The difference between the two IFN-alpha types lies in the distribution of the subtypes: this case, therefore, suggests that the difference in the subtype distribution may cause the different response of the RCC.
  • The histological diagnosis was pT3b G2 clear cell carcinoma.
  • He received intramuscular administration of 6 x 10(6) units of natural human IFN-alpha (Sumiferon) three times a week following the operation.
  • Finally, he was given intramuscular administration of 5 x 10(6) units of another natural human IFN-alpha (OIF) three times a week.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Interferon-alpha / classification. Interferon-alpha / therapeutic use. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Humans. Interleukin-2 / therapeutic use. Lung Neoplasms / secondary. Male. Middle Aged. Nephrectomy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14978941.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  •  go-up   go-down


6. Mignogna C, Staibano S, Altieri V, De Rosa G, Pannone G, Santoro A, Zamparese R, D'Armiento M, Rocchetti R, Mezza E, Nasti M, Strazzullo V, Montanaro V, Mascolo M, Bufo P: Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer; 2006;6:293
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.
  • BACKGROUND: A large number of renal cancer patients shows poor or partial response to chemotherapy and the mechanisms have not been still understood.
  • Multi-drug resistance is the principal mechanism by which many cancers develop resistance to chemotherapic drugs.
  • The role of the multi-drug resistant transporter (MDR-1/P-glycoprotein), the gene product of MDR-1, and that one of the so-called multi-drug resistance associated protein (MRP), two energy-dependent efflux pumps, are commonly known to confer drug resistance.
  • We studied MDR-1 expression in selected cases of renal cell carcinoma (RCC), clear cell type, with long-term follow-up, in order to establish its prognostic role and its possible contribution in the choice of post-surgical therapy.
  • Afterwards, we have found disease specific survival, adjusted for stages and independent of therapy: this difference of survival rates was statistically significant (p < 0.05).
  • Stage adjusted disease specific survival rate, according to MDR-1 expression and therapy in patients affected by RCC in early stage (stage I), has revealed that the group of patients with high MDR-1 expression and without adjuvant therapy showed poor survival (p < 0.05).
  • Cox multivariate regression analysis has confirmed that, in our cohort of RCC (clear cell type) patients, the strong association between MDR-1 and worse outcome is independent not only of the adjuvant therapy, but also of the other prognostic parameters (p < 0.05).
  • These results could be useful to predict cancer evolution and to choose the appropriate treatment: this is another step that can stimulate further promising and interesting investigations on broader study population.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / diagnosis. Kidney Neoplasms / metabolism. P-Glycoprotein / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1983 Jul;130(1):20-3 [6864906.001]
  • [Cites] J Urol. 1969 Mar;101(3):297-301 [5765875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735-8 [2444983.001]
  • [Cites] J Clin Oncol. 1987 Dec;5(12):1922-7 [3681376.001]
  • [Cites] Cancer. 1988 Apr 15;61(8):1639-51 [3349424.001]
  • [Cites] Eur Urol. 1988;15(3-4):271-6 [3215262.001]
  • [Cites] Semin Oncol. 1989 Feb;16(1 Suppl 1):12-9 [2465574.001]
  • [Cites] Semin Oncol. 1989 Feb;16(1 Suppl 1):3-11 [2645654.001]
  • [Cites] Semin Urol. 1989 Nov;7(4):199-206 [2694257.001]
  • [Cites] J Histochem Cytochem. 1990 Sep;38(9):1277-87 [1974900.001]
  • [Cites] Cancer Res. 1991 May 15;51(10):2720-6 [1673639.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2403-6 [1933777.001]
  • [Cites] Urol Int. 1991;47(4):203-12 [1781104.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 1):271-4 [1635115.001]
  • [Cites] Oncology. 1994 Jul-Aug;51(4):309-13 [7911563.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5351-6 [7923164.001]
  • [Cites] Cancer Lett. 1996 Apr 19;102(1-2):7-16 [8603381.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):892-8 [8631030.001]
  • [Cites] Br J Urol. 1997 Jul;80(1):11-7 [9240173.001]
  • [Cites] Nephron. 1997;77(3):284-9 [9375821.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1998 Jul;89(7):647-56 [9739586.001]
  • [Cites] Lancet. 1998 Nov 21;352(9141):1691-6 [9853456.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:361-98 [10331089.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] BJU Int. 2005 Mar;95 Suppl 2:8-13 [15759349.001]
  • [Cites] J Clin Pharmacol. 2005 Aug;45(8):872-7 [16027397.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):813-4 [16469556.001]
  • [Cites] Biol Pharm Bull. 2006 Jul;29(7):1449-53 [16819187.001]
  • [Cites] J Clin Pathol. 1999 Jun;52(6):450-4 [10562814.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2401-7 [10873092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8490-4 [10890910.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1065-75 [10964337.001]
  • [Cites] Urol Int. 2001;66(2):78-83 [11223748.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):39359-67 [11483599.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):658-64 [11857297.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):323-30 [11920581.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):121-8 [12017273.001]
  • [Cites] Biol Pharm Bull. 2002 Nov;25(11):1391-400 [12419946.001]
  • [Cites] J Urol. 2003 Mar;169(3):821-7 [12576793.001]
  • [Cites] Clin Pharmacol Ther. 2003 Mar;73(3):223-31 [12621387.001]
  • [Cites] Pharm Res. 2003 Sep;20(9):1394-400 [14567633.001]
  • [Cites] Int J Clin Pract. 2004 Apr;58(4):333-6 [15161115.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):503-8 [4005812.001]
  • (PMID = 17177989.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / P-Glycoprotein
  • [Other-IDs] NLM/ PMC1766933
  •  go-up   go-down


7. Piedra Lara JD, Tejido Sánchez A, García de la Torre JP, Capitán Manjón C, Cruceyra Betriu G, Leiva Galvis O: [Neuroendocrine renal carcinoma. Presentation of a case]. Arch Esp Urol; 2003 Mar;56(2):178-81
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine renal carcinoma. Presentation of a case].
  • [Transliterated title] Carcinoma renal neuroendocrino. Presentación de un caso.
  • OBJECTIVES: To report a new case of neuroendocrine renal cell carcinoma.
  • METHODS: We report the case of a 76-year-old woman with neuroendocrine renal cell carcinoma who underwent radical nephrectomy without any further adjuvant treatment.
  • CONCLUSIONS: Small cell renal cell carcinoma is a very rare neoplasia, affecting people over the age of 60 years, large in size, and metastatic at diagnosis.
  • It has bad prognosis, with short survival times.
  • The most adequate treatment has not been determined due to the scarcity of published cases; the combination of surgery and chemotherapy is the most frequently used.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Kidney Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12731447.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Izquierdo L, Truán D, Alvarez-Vijande R, Alcaraz A: [Large series of 114 cases with long-term follow-up of upper urinary tract urothelial tumors]. Actas Urol Esp; 2010 Mar;34(3):232-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Large series of 114 cases with long-term follow-up of upper urinary tract urothelial tumors].
  • [Transliterated title] Carcinoma urotelial de tracto urinario superior: 114 casos con largo seguimiento.
  • PURPOSE: Upper urinary tract urothelial carcinoma (UUTUC) represents 5% of all urothelial tumors and has uncertain prognostic.
  • Variables analyzed were age, sex, pathological tumor stage, histological tumor grade, CIS, tumor localization, multiplicity, bladder cancer history, pathological nodes and adjuvant chemotherapy.
  • Fifteen patients presented pathological nodes at the moment of diagnosis.
  • Fourteen percent of 114 patients received adjuvant treatment (Platin-based regimen).
  • Mean follow-up: 74.8 months; 30.7% of the patients developed tumor progression.
  • Mean time of tumor progression: 12.2 months and 23.3 months for cancer-specific death.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy. Ureteral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416239.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Cioppa T, Marrelli D, Neri A, Caruso S, Pedrazzani C, Malagnino V, Pinto E, Roviello F: A case of small-cell gastric carcinoma with an adenocarcinoma component and hepatic metastases: treatment with systemic and intra-hepatic chemotherapy. Eur J Cancer Care (Engl); 2007 Sep;16(5):453-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small-cell gastric carcinoma with an adenocarcinoma component and hepatic metastases: treatment with systemic and intra-hepatic chemotherapy.
  • Primary small-cell carcinoma (SmCC) of the stomach is a rare neoplasm with a poor prognosis and unclear histogenesis: to date, only 50 cases, including ours, have been reported in the literature.
  • In this paper, the authors present a clinical case and the surgical treatment of an adult with a SmCC of the stomach associated with gastric adenocarcinoma.
  • After laparotomy, a large neoplasm with locoregional extension and multiple liver metastases were found.
  • A palliative resection, subtotal gastrectomy, was performed, followed by systemic and intra-hepatic chemotherapy: computed tomography scan demonstrated a marked response, but the patient died 15 months after the operation.
  • A review of the literature showed that the diagnosis of gastric SmCC is based on immunohistochemical findings.
  • Our experience confirmed the high aggressiveness of this neoplasm, which is generally diagnosed in advanced stage and is unresponsive to chemotherapy, but the combined use of systemic and intra-hepatic chemotherapy shows an acceptable result in a palliative care perspective.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / secondary. Kidney Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Gastrectomy. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760934.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Roupret M, Peyromaure M, Hupertan V, Larousserie F, Vieillefond A, Thiounn N, Dufour B, Zerbib M, Debre B, Mejean A: [Bellini renal cell carcinoma. Diagnosis and treatment]. Prog Urol; 2004 Sep;14(4):564-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bellini renal cell carcinoma. Diagnosis and treatment].
  • [Transliterated title] Carcinome à cellules rénales de Bellini: diagnostic et traitement.
  • The Bellini collecting duct carcinoma is a very rare form of renal cell carcinoma (1%).
  • The diagnosis should be considered in patients presenting with marked deterioration of the general status and/or the presence of a very large invasive renal tumour on abdominal CT scan.
  • The overall 2-year survival rate of Bellini carcinoma is about 20%.
  • As the prognosis is very poor, even despite radical nephrectomy, biopsy may be performed as the first-line procedure when the diagnosis is suspected.
  • In the case of primary metastatic Bellini carcinoma, radical nephrectomy alone appears to be useless and dangerous except for analgesic purposes or in the context of new multicentre chemotherapy protocols, combining gemcitabine and cisplatin, currently under evaluation.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776915.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 29
  •  go-up   go-down


11. Schmidinger M, Hejna M, Zielinski CC: Aldesleukin in advanced renal cell carcinoma. Expert Rev Anticancer Ther; 2004 Dec;4(6):957-80
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aldesleukin in advanced renal cell carcinoma.
  • Renal cell carcinoma accounts for 2-3% of all malignancies.
  • The most common subtype [85%] is the clear cell variant.
  • A total of 30% of patients present with metastatic disease at diagnosis and another 30-40% will develop metastases during the course of the disease.
  • Conventional cancer treatment is not effective, but cytokines including recombinant interleukin-2 (aldesleukin) have demonstrated clinical activity of various degrees.
  • This drug profile provides a review of the literature on studies using aldesleukin in patients with metastatic renal cell carcinoma.
  • Aldesleukin has been used in different dose schedules applying various administration routes, as either monotherapy or in combination with other cytokines, chemotherapy, endocrine treatment and adoptive cellular immunotherapy.
  • Although a large number of randomized trials have been performed with different treatment strategies, it still remains uncertain whether the dose or combination of aldesleukin with other agents substantially influence treatment outcome.
  • It appears that factors other than those that are treatment related are responsible for the course of the disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Interleukin-2 / analogs & derivatives. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Humans. Immunotherapy, Adoptive. Randomized Controlled Trials as Topic. Recombinant Proteins / administration & dosage. Recombinant Proteins / pharmacokinetics. Recombinant Proteins / pharmacology. Recombinant Proteins / therapeutic use

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606326.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 0 / Recombinant Proteins; M89N0Q7EQR / aldesleukin
  • [Number-of-references] 179
  •  go-up   go-down


12. Sausville JE, Hernandez DJ, Argani P, Gearhart JP: Pediatric renal cell carcinoma. J Pediatr Urol; 2009 Aug;5(4):308-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric renal cell carcinoma.
  • Renal cell carcinoma (RCC) comprises about 5% of pediatric renal neoplasms.
  • It is generally symptomatic at diagnosis, and most children with RCC present with more locally advanced disease than do adults.
  • Contemporary investigation of pediatric RCC has demonstrated that a large percentage of these tumors bear cytogenetic translocations involving the MiT family of transcription factors.
  • Surgical therapy for these children resembles operative intervention for adult RCC, though debate continues about the precise role of lymph node dissection.
  • There are no adequately powered studies to support conclusions about adjuvant or neoadjuvant chemotherapy for children with RCC.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms. Neoplasms, Second Primary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443274.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 45
  •  go-up   go-down


13. Preechawai P, Amrith S, Yip CC, Goh KY: Orbital metastasis of renal cell carcinoma masquerading as cysticercosis. Orbit; 2008;27(5):370-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastasis of renal cell carcinoma masquerading as cysticercosis.
  • Metastasis to the orbital soft tissues is relatively uncommon.
  • We report a rare case of renal cell carcinoma with orbital metastasis as the first clinical manifestation.
  • An incisional biopsy performed showed metastatic poorly differentiated carcinoma.
  • Magnetic resonance imaging (MRI) of the spine showed extensive vertebral metastasis to the thoracic and lumbosacral spine and the iliac bone, with an incidental detection of a large mass from the right kidney.
  • Further MRI of abdomen and chest showed a large right renal mass presumed to be a renal cell carcinoma with extension into the right renal vein, intra-abdominal lymph nodes, and peritoneum.
  • Renal cell carcinoma does not respond to chemotherapy, immunotherapy, or radiation; because of the disease's advanced stage, the patient received palliative treatment.
  • There have been only two other reports in the literature of metastatic renal cell carcinoma in the orbit where the proptosis was the initial presenting feature similar to our case.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Cysticercosis / diagnosis. Eye Infections, Parasitic / diagnosis. Kidney Neoplasms / pathology. Orbital Diseases / diagnosis. Orbital Neoplasms / secondary. Spinal Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Exophthalmos / diagnosis. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Palliative Care

  • Genetic Alliance. consumer health - Cysticercosis.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836935.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Liu LN, Chen GY, Wang P, Zhang CH, Huang SF: [Papillary renal cell carcinoma: clinico-pathologic studies of 33 cases]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):102-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary renal cell carcinoma: clinico-pathologic studies of 33 cases].
  • OBJECTIVE: To investigate the morphologic features, differential diagnosis, prognosis and histogenesis of papillary renal cell carcinoma (PRCC).
  • Light microscopic observation, immunohistochemical assay of EMA, CK7, CD10, Vim, 34 beta E12 by tissue chip were performed.
  • Tumors were of two major types: basophilic type (n = 10), with small cuboid cell and pale cytoplasm (n = 10), 9 of them were low in Fuhrman grading; eosinophilic type (n = 22) with large columnar cells, rich in eosinophilic cytoplasm, 19 of them were high in Fuhrman grading.
  • The remaining case was of clear cell type.
  • The basophilic tumors were all positive for distal tubule marker EMA/CK7, none for proximal tubule marker CD10, 7 tumors positive for Vim.
  • The prognosis of PRCC was worse than that of chromophobe renal cell carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Keratin-7. Keratins / metabolism. Kidney Tubules / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Neprilysin / metabolism. Survival Rate. Vimentin / metabolism

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946550.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


15. Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V, Dutcher JP, Ghavamian R: Renal medullary carcinoma: the Bronx experience. Urology; 2007 Nov;70(5):878-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal medullary carcinoma: the Bronx experience.
  • OBJECTIVES: Renal medullary carcinoma (RMC) is a devastating and extremely rare malignancy primarily afflicting young men with sickle cell trait.
  • The clinical patient characteristics, presentations, treatments, and outcomes were recorded.
  • RESULTS: All 9 patients had sickle cell trait, the male/female ratio was 6:3, and the age range was 13 to 31 years.
  • One patient was deemed to have unresectable disease by the operating surgeon, and one was given initial chemotherapy after biopsy of a metastatic lesion.
  • The neoadjuvant therapies varied.
  • CONCLUSIONS: Our urban setting likely explains our relatively large experience with this rare and extremely aggressive tumor.
  • An early diagnosis is critical, and a high index of suspicion should be given to any individual with sickle cell trait and new-onset hematuria, especially in the setting of a right-sided mass.
  • Prospective trials are needed for chemotherapy/immunotherapy, because surgical intervention alone is inadequate.
  • [MeSH-major] Carcinoma, Medullary. Kidney Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068443.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


16. Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol; 2003 Aug;47(2):155-69
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ureter and renal pelvis.
  • Transitional cell carcinoma (TCC) of ureter and renal pelvis is relatively uncommon.
  • Nephroureterectomy with bladder cuff excision has been the mainstay of treatment.
  • Local resection may be appropriate for distal ureteral lesions especially when the disease is low grade and stage.
  • Adjuvant topical therapies appear to be safe but confirmation of any benefits awaits the results of further large studies.
  • Adjuvant radiotherapy is ineffective, and systemic chemotherapy results in a low complete response rate for patients with metastases.
  • [MeSH-major] Carcinoma, Transitional Cell. Kidney Neoplasms. Ureteral Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Kidney Pelvis / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12900009.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 146
  •  go-up   go-down


17. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev; 2008 May;34(3):193-205
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
  • Renal cell carcinoma (RCC), the most common form of kidney cancer, initially has an asymptomatic clinical course; 25-30% of patients present with metastatic disease at time of diagnosis.
  • Metastatic RCC (mRCC) is one of the most treatment-resistant malignancies; outcomes are generally poor and median survival after diagnosis is less than one year.
  • Surgery and chemotherapy have limited or no effect, leaving mRCC patients underserved in the realm of cancer treatment.
  • With a shift in treatment of mRCC to novel therapies, such as molecularly targeted therapies (MTTs) (e.g., sorafenib and sunitinib), clinicians, payers, and other healthcare decision-makers must re-evaluate the optimal role for new treatments.
  • The estimated economic burden of mRCC is large; $107-$556 million (2006 USD) in the US and $446 million-$1.6 billion (2006 USD) collectively in select countries worldwide.
  • [MeSH-major] Carcinoma, Renal Cell / economics. Carcinoma, Renal Cell / epidemiology. Kidney Neoplasms / economics. Kidney Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313224.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 85
  •  go-up   go-down


18. Porcaro AB, D'Amico A, Novella G, Curti P, Ficarra V, Antoniolli SZ, Martignoni G, Matteo B, Malossini G: Primary lymphoma of the kidney. Report of a case and update of the literature. Arch Ital Urol Androl; 2002 Mar;74(1):44-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the kidney. Report of a case and update of the literature.
  • MATERIALS AND METHODS: A 48-year-old woman underwent surgery for the presumed diagnosis of renal cell carcinoma with bilateral adrenal metastases.
  • RESULTS: The neoplasm was assessed as primary renal non-Hodgkin high grade lymphoma, diffuse large B-cell type.
  • Unfortunately, 5 weeks later the patient was lost since missing chemotherapy and follow-up.
  • Several histogenetic theories of the disease have been postulated since the kidney does not normally contain lymphoid tissue.
  • Investigators reported many classes of non-Hodgkin lymphoma which include large, small, intermediate and mixed cell types with high, intermediate or low grade histologies.
  • The disease may present with progressive renal failure of either oliguric or non oliguric type.
  • Imaging studies in diagnosing and staging primary renal lymphomas include ultrasound examination (US) and computed tomography (CT); there are also some reports of magnetic resonance imaging (MRI).
  • Renal biopsy is important in assessing the diagnosis of PRL as well as of acute renal failure for bilateral lymphomatous infiltration of the kidneys.
  • Up to now, there are no standard treatment modalities for this entity since the small number of cases reported.
  • Multidrug chemotherapy is mandatory for high grade lymphoma and when the disease is diagnosed preoperatively.
  • High dose chemotherapy in the future may offer a curative approach in primary bilateral renal disease and without end-stage renal disease.
  • Prognosis may be improved by early detection of disease and by performing systemic chemotherapy.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12053451.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Number-of-references] 33
  •  go-up   go-down


19. García-Campelo R, Quindós M, Vázquez DD, López MR, Carral A, Calvo OF, Soto JM, Grande E, Durana J, Antón-Aparicio LM: Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma. Anticancer Drugs; 2010 Jan;21 Suppl 1:S13-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma.
  • A 75-year-old-man, with a 2-month history of abdominal pain, underwent a standard diagnostic workup that included a CT scan that showed a large right renal mass and subcentimeter nodes in the right and left lung lobes.
  • In December 2003, the patient underwent right nephrectomy with adrenalectomy and a diagnosis of renal cell carcinoma (pT3N0M0 stage) was made.
  • No further treatment was proposed and patient was followed up regularly.
  • In October 2006, the annual gastrointestinal endoscopy showed asymptomatic multilobulated and polypoid masses in the gastric fundus and gastric body that corresponded to metastasis of the renal carcinoma that had been resected three years ago.
  • Surgical treatment was refused and oral treatment with sunitinib (50 mg/day consecutively for 4 weeks followed by 2 weeks off) was initiated.
  • Patient completed one cycle and development of acute toxicity (grade 3 asthenia, anorexia and mucositis) led to treatment interruption.
  • After recovering from acute toxicity, the patient was proposed to reinitiate treatment with dose reduction, but he refused any medical treatment.
  • PET scan six months after treatment confirmed complete gastric response.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / secondary. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / secondary. Indoles / therapeutic use. Kidney Neoplasms / pathology. Protein Kinase Inhibitors / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Adrenalectomy. Aged. Humans. Male. Neoplasm Metastasis. Nephrectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110781.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


20. Dufau JP, Patte JH, Ceccaldi B, Fagot T, Sylvestre A, Le Vagueresse R: [Non-Hodgkin lymphoma mimicking renal carcinoma: apropos of 1 case of follicular lymphoma]. Ann Pathol; 2000 May;20(3):253-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin lymphoma mimicking renal carcinoma: apropos of 1 case of follicular lymphoma].
  • The median age at diagnosis is 64 years with a male predominance.
  • Clinical and radiological findings generally evoke renal carcinoma.
  • Histologically, tumors are usually large B-cell lymphomas.
  • The existence of renal non-Hodgkin lymphoma mimicking renal carcinoma must be recognized.
  • Nephrectomy followed by chemotherapy permits long disease free survival.
  • [MeSH-major] Kidney Neoplasms. Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Humans. Nephrectomy. Tomography, X-Ray Computed


21. Stifelman MD, Handler T, Nieder AM, Del Pizzo J, Taneja S, Sosa RE, Shichman SJ: Hand-assisted laparoscopy for large renal specimens: a multi-institutional study. Urology; 2003 Jan;61(1):78-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hand-assisted laparoscopy for large renal specimens: a multi-institutional study.
  • One of the theoretical benefits of HAL is the ability to manage large renal specimens, which we defined as tumors greater than 7 cm, and tumors in obese patients.
  • Of the 95 patients, 32 underwent HAL for large tumors (7 cm or greater) and 41 had a body mass index of 31 or greater.
  • Obese patients had statistically significantly higher American Society of Anesthesiologists classifications, longer operative times (214 versus 176 minutes), and longer convalescences (21 versus 17.5 days) compared with nonobese patients.
  • CONCLUSIONS: HAL provides a safe, reproducible, and minimally invasive technique to remove large renal tumors and renal tumors in the obese.
  • [MeSH-major] Kidney Neoplasms / surgery. Laparoscopy / methods. Nephrectomy / methods
  • [MeSH-minor] Blood Loss, Surgical / prevention & control. Blood Loss, Surgical / statistics & numerical data. Body Mass Index. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Comorbidity. Convalescence. Female. Humans. Kidney / pathology. Length of Stay. Male. Middle Aged. Narcotics / therapeutic use. Obesity / diagnosis. Obesity / epidemiology. Pain, Postoperative / drug therapy. Postoperative Complications / epidemiology. Prospective Studies. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12559271.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Narcotics
  •  go-up   go-down


22. Yoshii T, Horiguchi A, Shirotake S, Tobe M, Hayakawa M, Sumitomo M, Asano T: [Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma]. Hinyokika Kiyo; 2010 Nov;56(11):639-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography showed urinoma around the left kidney and retrograde pyelography showed a diffuse filling defect in the left ureter and a rupture of the upper portion of that ureter.
  • A urine cytology specimen from the left ureter was class V, suggesting undifferentiated carcinoma or malignant lymphoma.
  • An open laparotomy revealed a nodule on the omentum and diffuse fibrosis around both ureters, and the histopathological diagnosis was diffuse large B-cell lymphoma.
  • The patient' s ureteral stenosis disappeared after she received six cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone and rituximab) chemotherapy.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / complications. Ureteral Diseases / etiology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187710.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Boratyńska M, Watorek E, Smolska D, Patrzałek D, Klinger M: Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc; 2007 Nov;39(9):2736-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibition of mTOR is a target for anticancer drugs in posttransplant malignancies.
  • The influence of conversion to sirolimus after malignancy diagnosis was investigated on patient and renal allograft survivals.
  • The 20 renal allograft recipients (4 women, 16 men) of ages 26 to 73 years (mean, 59 years) developed malignancies within 6 to 172 months (mean, 53 months) after transplantation.
  • Three patients developed posttransplant lymphoproliferative disease (PTLD); four, Kaposi sarcoma, three, lung cancer; two, malignant melanoma; two, breast cancer; two, renal cell carcinoma; one, Merkel cell carcinoma; one, cutaneous T-cell lymphoma; one, larynx cancer; and one, gingival cancer.
  • After tumor diagnosis, calcineurin inhibitors, azathioprine, or mycophenolate mofetil (MMF) were discontinued abruptly and sirolimus introduced (2 mg/d; target trough level, 4.0 to 8.0 ng/mL).
  • The observation time of sirolimus therapy was 4 to 48 months (mean, 14 months).
  • Two patients with PTLD (large B-cell lymphoma) and four with Kaposi sarcoma had full regressions.
  • Eleven patients (larynx cancer, melanoma, breast cancer, T-cell lymphoma, renal cell carcinoma, Merkel cell carcinoma, and skin lymphoma) in addition to sirolimus therapy, underwent oncologic treatment, namely, surgery and/or chemotherapy.
  • One patient with T-cell lymphoma lost his graft; in the remaining patients, serum creatinine level was stable.
  • In conclusion, Conversion to sirolimus resulted in regression of large B-cell lymphoma and Kaposi sarcoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Kidney Transplantation / adverse effects. Lymphoma, B-Cell / drug therapy. Neoplasms / drug therapy. Neoplasms / epidemiology. Postoperative Complications / drug therapy. Sarcoma, Kaposi / drug therapy. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunosuppressive Agents / therapeutic use. Lymphoproliferative Disorders / epidemiology. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous


24. Galán Brotons A, Borrás-Blasco J, Rosique-Robles JD, Vicent Verge JM, Casterá ME: Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. Clin Transl Oncol; 2008 Dec;10(12):844-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
  • A woman diagnosed of a renal cell carcinoma in 1989 had a metastatic kidney cancer localised in subcutaneous nodules, gut and lung in 2007.
  • Sorafenib treatment was initiated a 400 mg orally twice a day.
  • The patient developed generalised erythematous skin eruptions and two weeks later a widespread erythematous maculopapular eruption located exclusively on the legs and arms, along with an objective response.
  • The most likely cause of the generalised erythematous skin eruptions was considered to be sorafenib because of the close temporal relationship between exposure to the drug and onset of symptoms.
  • Furthermore, a relationship between sorafenib skin toxicity and treatment efficacy was observed.
  • This therapeutic efficacy of EGFR inhibitors and cutaneous side effects should be better assessed in large cohorts or trials to determine whether the skin toxicity of patients can be linked to an objective antitumour response.
  • [MeSH-major] Benzenesulfonates / adverse effects. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Dermatitis, Exfoliative / chemically induced. Kidney Neoplasms / drug therapy. Pyridines / adverse effects. Pyridines / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Drug Eruptions / diagnosis. Female. Humans. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Skin / drug effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2007 Apr;12(4):426-37 [17470685.001]
  • [Cites] South Med J. 2007 Mar;100(3):328-30 [17396743.001]
  • [Cites] JAMA. 1998 May 27;279(20):1613-4 [9613909.001]
  • [Cites] J Am Acad Dermatol. 2007 Mar;56(3):527-8 [17241689.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(4):548-56 [16426838.001]
  • [Cites] Tumori. 2007 Mar-Apr;93(2):201-3 [17557570.001]
  • [Cites] Clin Transl Oncol. 2007 Oct;9(10):671-3 [17974528.001]
  • [Cites] Ann Pharmacother. 2006 Feb;40(2):241-50 [16403849.001]
  • (PMID = 19068457.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


25. Kose F, Sakalli H, Mertsoylu H, Sezer A, Kocer E, Tokmak N, Kilinc F, Ozyilkan O: Primary renal lymphoma: report of four cases. Onkologie; 2009 Apr;32(4):200-2
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORTS: Here, we report 4 cases of primary renal lymphoma presenting with unilateral renal masses, which after radiological and clinical examination were assumed to be renal cell carcinoma.
  • Histopathological subtypes were diffuse large B cell lymphoma in 2 cases and non-Hodgkin's lymphoma of small B cell type in the others.
  • While 3 of the patients were treated with systemic chemotherapy, the fourth patient refused chemotherapy.
  • 2 patients (no. 2 and 3) were still in complete remission and were followed regularly in the second and first year after diagnosis, respectively.
  • CONCLUSIONS: Since it is difficult to diagnose primary renal lymphoma, most patients with this kind of tumor undergo radical nephrectomy, and diagnosis of primary renal lymphoma is delayed.
  • The authors believe that both the delayed diagnosis due to anatomical difficulties and the histological aggressive characteristics of this disease are equally responsible for the poor outcome in the case of primary renal lymphoma.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Lymphoma / diagnosis. Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19372716.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


26. Yeh J, Frieze D, Martins R, Carr L: Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann Pharmacother; 2010 Jun;44(6):1010-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors.
  • BACKGROUND: Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody approved for use in treatment of patients with metastatic breast, colorectal, and non-small cell lung cancer.
  • The manufacturer recommends monitoring for the development of proteinuria but does not provide specific recommendations, except to discontinue treatment if the patient develops nephrotic syndrome.
  • OBJECTIVE: To determine the incidence and severity of elevated proteinuria and the frequency of changes in bevacizumab administration due to elevated proteinuria; secondary objectives included analysis of the cost of routine proteinuria monitoring and the relationship of proteinuria with other patient comorbidities such as diabetes, hypertension, chronic kidney disease, and viral hepatitis.
  • METHODS: A retrospective chart review was performed at the University of Washington Medical Center, a large academic teaching hospital, and its affiliated ambulatory clinics at the Seattle Cancer Care Alliance.
  • Only 1.6% of these patients developed grades 3-4 proteinuria.
  • All 4 of these patients had a history of hypertension, 2 of these patients had prior chronic kidney disease, and 3 patients had prior viral hepatitis.
  • Elevated proteinuria affected treatment decisions in 2% of patients.
  • CONCLUSIONS: These results demonstrate that the development of grades 3-4 proteinuria with bevacizumab is rare and affects treatment decisions in few patients with metastatic solid tumor.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Colorectal Neoplasms / drug therapy. Proteinuria / chemically induced. Proteinuria / diagnosis. Vascular Endothelial Growth Factor A
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20460557.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


27. Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, Boccon-Gibod L, Denoux Y, Ferlicot S, Forest E, Fromont G, Hintzy MC, Laghouati M, Sibony M, Tucker ML, Weber N, Teh BT, Vieillefond A: Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol; 2008 May;32(5):656-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report clinicopathologic features of a large series of renal translocation carcinomas from a multicentric study.
  • Diagnosis was performed by cytogenetic examination of fresh material and/or by immunochemistry with antibodies directed against the C-terminal part of transcription factor E3 (TFE3) and native transcription factor EB (TFEB) proteins.
  • Antibodies against CK7, CD10, vimentin, epithelial membrane antigen, AE1-AE3, E-cadherin, alpha-methylacyl-coenzyme A racemase, melan A, and HMB45 were tested on tissue microarrays.
  • Two patients had a previous history of chemotherapy and 1 had a history of renal failure.
  • Mixed papillary and nested patterns with clear and/or eosinophilic cells represented the most consistent histologic appearance, with common foci of calcifications regardless of the type of translocation.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Gene Expression Profiling. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / analysis. Biomarkers, Tumor / analysis. Child. Cytogenetic Analysis. Female. Gene Expression Regulation, Neoplastic. Genome. Humans. Infant. Male. Neoplasm Proteins / analysis. Nephrectomy. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344867.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / TFE3 protein, human; 0 / TFEB protein, human
  •  go-up   go-down


28. McKeage K, Wagstaff AJ: Sorafenib: in advanced renal cancer. Drugs; 2007;67(3):475-83; discussion 484-5
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • black triangle Sorafenib is an oral multikinase inhibitor that targets the mitogen-activated protein kinase signalling pathway and receptor tyrosine kinases involved in tumour proliferation and angiogenesis.black triangle In the large, phase III, randomised, double-blind, multicentre Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) of patients with advanced clear-cell renal cell cancer in whom previous systemic therapy had failed, median progression-free survival was doubled in patients receiving sorafenib compared with those receiving placebo (5.9 vs 2.8mo).black triangle Significantly more patients receiving sorafenib than those receiving placebo in the phase III trial experienced complete or partial responses or stable disease.black triangle Age, risk-assessment score, prior treatment, metastasis in lung or liver, or time from diagnosis did not affect the improved progression-free survival in sorafenib recipients.black triangle In a randomised, phase II discontinuation trial of patients with advanced renal cancer, in which only those showing stable disease with sorafenib were randomised to further sorafenib or placebo, more patients receiving sorafenib were free of progressive disease 12 weeks after randomisation than were those receiving placebo, and median progression-free survival was longer in sorafenib recipients.black triangle In clinical trials, most drug-related adverse events were mild to moderate in severity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Cell Proliferation / drug effects. Humans. MAP Kinase Signaling System / drug effects. Neovascularization, Pathologic / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Randomized Controlled Trials as Topic. Receptor Protein-Tyrosine Kinases / drug effects

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1363-9 [16446323.001]
  • [Cites] Expert Opin Investig Drugs. 2005 Oct;14(10):1251-8 [16185167.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6861-9 [16007148.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2505-12 [16636341.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(4):548-56 [16426838.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):685-92 [16133532.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):677-85 [15827342.001]
  • [Cites] Int J Clin Pharmacol Ther. 2003 Dec;41(12):620-1 [14692720.001]
  • [Cites] Int J Clin Pharmacol Ther. 2004 Nov;42(11):648-9 [15598034.001]
  • [Cites] BJU Int. 2005 Jun;95(8):1153-61 [15877725.001]
  • [Cites] Eur J Cancer. 2005 May;41(8):1106-8 [15911232.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Anticancer Drugs. 2005 Aug;16(7):709-17 [16027518.001]
  • [Cites] Int J Clin Pharmacol Ther. 2002 Dec;40(12):580-1 [12503822.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1855-61 [15870716.001]
  • (PMID = 17335301.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 30
  •  go-up   go-down






Advertisement